Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent versus continuous androgen deprivation with Eligard in relapsing or locally advanced prostate cancer
2005-004094-25Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of leuprolide in prostate adenocarcinoma and prostate cancer (PCa) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Time to PSA progression. Started Dec 2005; status: completed.
02
Drugs
leuprolide
03
Conditions
prostate adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on 2005-004094-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004094-25.